RCS - OptiBiotix Health - Presentation at ProBiota 2024

OptiBiotix HealthAnnouncement

05/02/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240205:nRSE7641Ba&default-theme=true

RNS Number : 7641B  OptiBiotix Health PLC  05 February 2024

OptiBiotix Health plc

("OptiBiotix" or the "Company")

 

Presentation at ProBiota 2024

 

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing
compounds to tackle obesity, high cholesterol and diabetes, announces it will
be presenting research and meeting potential partners at ProBiota 2024 between
7-9 February 2024, in Milan.

 

ProBiota is the leading annual event for the global prebiotic, probiotic and
the microbiome focused food and pharma industries. The conference is world
renowned for scientists and industry leaders who are seeking to translate the
latest science into new products in the supplements and ingredients market.

 

The Company will be presenting on novel methods to design a range of prebiotic
approaches which stimulate the growth of probiotics of commercial interest.
These can be used as excipients in probiotic capsules, tablets, and sachets to
selectively support the growth of the probiotic and enhance its health
benefit.  These synbiotics represent an area of growing market interest as a
means to bring innovation and differentiation into the probiotic market with a
forecast CAGR of 8.2% between 2022 and 2027 Synbiotic Products Market Size
& Share Analysis - Industry Research Report - Growth Trends
(mordorintelligence.com)
(https://www.mordorintelligence.com/industry-reports/synbiotic-products-market)

 

Commenting, Stephen O'Hara, CEO of OptiBiotix said: "We were pleased to be
presenting our research on synbiotics at ProBiota. Attending conferences like
ProBiota, which attract scientists from around the world, allow us to present
our work to industry and increases awareness of OptiBiotix and its products.
This often attracts commercial interest in our technology and helps build the
product pipeline in different territories and with different partners. This
increases the scale of the opportunity, and the potential value of
OptiBiotix."

 

For further information, please contact:

 OptiBiotix Health plc                        www.optibiotix.com (http://www.optibiotix.com/)
 Neil Davidson, Chairman  Contact via Walbrook below
 Stephen O'Hara, Chief Executive

 Peterhouse Capital Limited (Broker)          Tel: 020 7220 9797
 Duncan Vasey / Lucy Williams

 Walbrook PR Ltd                              Mob: 07876 741 001
 Anna Dunphy

 

About OptiBiotix - www.optibiotix.com (http://www.optibiotix.com/)

OptiBiotix Health plc (AIM: OPTI) brings science to the development of
compounds which modify the human microbiome - the collective genome of the
microbes in the body - in order to prevent and manage human disease and
promote wellness.

 

OptiBiotix has an extensive R&D programme working with leading academics
in the development of microbial strains, compounds, and formulations which are
used as active ingredients and supplements. More than twenty international
food and healthcare supplement companies have signed agreements with
OptiBiotix to incorporate their human microbiome modulators into a wide range
of food products and drinks.

 

OptiBiotix is also developing its own range of consumer supplements and health
products. The Company's current areas of focus include obesity, cardiovascular
health, and diabetes.

 

This communication is a "Reach" announcement. Reach is a non-regulatory news
service. By using this service an issuer is confirming that the information
contained in this announcement is of a non-regulatory nature. Information
required to be notified under the AIM Rules for Companies, Market Abuse
Regulation or other regulation would be disseminated as an RNS regulatory
announcement and not on RNS Reach.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRABLGDDGDGDGSB